The Ever Shifting Pharmaceutical Marketplace – Biosimilars and Interchangeability
Blog Posts
Fuld & Company
The FDA recently approved Amjevita (adalimumab-atto), Amgen’s adalimumab biosimilar product for seven inflammatory indications in adult patients1. It was the […]